ReviewGastro hep advances2026
Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis.
Review in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Programmed cell death protein-(ligand) 1 (PD-[L]1) inhibitors have improved survival outcomes for patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). Given the higher incidence of GC mortality in Asian vs non-Asian populations coupled with some differences in etiology and treatment, this meta-analysis compared survival outcomes associated with first-line (1L) PD-(L)1 inhibitors plus chemotherapy in Asian and non-Asian patients with advanced GC/GEJC. Methods: A systematic literature review was undertaken to identify randomized, phase III studies examining efficacy and safety of 1L PD-(L)1 inhibitor plus chemotherapy treatment in patients with advanced GC/GEJC. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were pooled using fixed and random effects models. Safety data were summarized descriptively. Results: Seven studies (3669 Asian and 3104 non-Asian patients) were included; 76% of patients had GC, ∼40% were aged ≥65 years, and 71% were male. PD-(L)1 inhibitors plus chemotherapy improved OS (HR, 0.80; 95% confidence interval [CI], 0.75-0.84) and PFS (HR, 0.75; 95% CI, 0.71-0.80) in the overall population. For the Asian and non-Asian regional breakdown, similar benefits were observed for OS (HR, 0.79; 95% CI, 0.73-0.85 and HR, 0.81; 95% CI, 0.74-0.89, respectively), with a comparable effect size for PFS (HR, 0.70; 95% CI, 0.64-0.76 and HR, 0.79; 95% CI, 0.70-0.89, respectively). Treatment-related adverse event rates were consistent across PD-(L)1 inhibitor plus chemotherapy (94%-98%) and placebo plus chemotherapy (92%-97%) groups. Conclusion: 1L PD-(L)1 inhibitors plus chemotherapy improved survival outcomes in patients with advanced GC/GEJC, regardless of Asian/non-Asian regional breakdown. These findings suggest that survival benefit is generalizable and independent of recruitment region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.